Androgen receptor expression relative to estrogen receptor expresion (AR/ ER) and relationship with a gene proliferation signature in ER-positive breast cancer
PDF (Español (España))
HTML (Español (España))


Breast Neoplasms
Receptors Androgen
Receptors Estrogen
Cell Proliferation
Gene Expression Profiling
Molecular typing

How to Cite

Rangel, N., Aristizábal, A. F., & Rondón, M. (2019). Androgen receptor expression relative to estrogen receptor expresion (AR/ ER) and relationship with a gene proliferation signature in ER-positive breast cancer. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 6(3), 164–169.


Purpose: Previously have been reported that breast cancers (BC) with high expression of AR relative to estrogen receptor (AR/ER ?2) are associated with worse prognosis. The aim of this study was to evaluate the relationship between the AR/ER ratio and a gene proliferation signature in ER - positive (ER+) tumors.
Methods: 1093 BC samples with gene expression data were obtained from NCI Genomic Data Commons. Bioinformatic analysis were performed to establish gene expression levels of AR, ER and also levels of cellular proliferation markers AURKb, BUB1B, BUB1, CDK1 and CHEK1. Furthermore, molecular subtypes were defined based on the PAM50 bioclassifier.
Results: 835 cases were reported as ER+ and, from them, 58 tumors (7%) showed higher level of AR respect to ER (AR/ ER ?2). These last cases had significantly higher levels of cellular proliferation markers, compared with AR/ER <2 ratio cases (p = 0.02) and were mainly classified as luminal B and HER2- enriched molecular subtypes (76.5%).
Conclusions: our results confirm previous reports and suggest that BC cases with ratio AR/ER ?2 are associated with tumors having more aggressive biological behavior. Moreover, it reinforces the insight of use of AR-inhibitors for treatment of ER+ BC patients which have higher AR expression levels.
PDF (Español (España))
HTML (Español (España))


1. Early Breast Cancer Trialists’ Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patientlevel meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.
2. Hu R, Dawood S, Holmes M, Collins L, Schnitt S, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867-74.
3. Park S, Koo J, Park H, Kim J, Choi S, Lee J, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488-92.
4. Aleskandarany M, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, et al. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat. 2016;159(2):215-27.
5. Bozovic-Spasojevic I, Zardavas D, Brohee S, Ameye L, Fumagalli D, Ades F, et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res. 2017;23(11):2702-12.
6. Castellano I, Allia E, Accortanzo V, Vandone A, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607-17.
7. Niemeier L, Dabbs J, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205-12.
8. Asano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers (Basel). 2017;9(1).
9. Hilborn E, Gacic J, Fornander T, Nordenskjold B, Stal O, Jansson A. Androgen receptor expression predicts beneficial tamoxifen response in estrogen receptor-alpha-negative breast cancer. Br J Cancer. 2016;114(3):248-55.
10. Jiang H, Kuang X, Sun W, Xu Y, Zheng Y, Liu Y, et al. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget. 2016;7(27):41285-93.
11. Luo X, Shi Y, Li Z, Jiang W. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29(6):585-90.
12. Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351-62.
13. Qu Q, Mao Y, Fei X, Shen K. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013;8(12):e82650.
14. Vera-Badillo F, Templeton A, de Gouveia P, Diaz-Padilla I, Bedard P, AlMubarak M, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(1):djt319.
15. Peters A, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131-40.
16. Cops E, Bianco-Miotto T, Moore N, Clarke C, Birrell S, Butler L, et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008;110(3-5):236-43.
17. Greeve M, Allan R, Harvey J, Bentel J. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). J Mol Endocrinol. 2004;32(3):793-810.
18. Macedo L, Guo Z, Tilghman S, Sabnis G, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66(15):7775-82.
19. Need E, Selth L, Harris T, Birrell S, Tilley W, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. 2012;26(11):1941-52.
20. Buchanan G, Birrell S, Peters A, Bianco-Miotto T, Ramsay K, Cops E, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005;65(18):8487-96.
21. Birrell S, Bentel J, Hickey T, Ricciardelli C, Weger M, Horsfall D, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52(5):459-67.
22. Lin H, Sun M, Lin C, Tang H, London D, Shih A, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol. 2009;113(3-5):182-8.
23. Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.
24. Robinson J, Macarthur S, Ross-Innes C, Tilley W, Neal D, Mills I, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30(15):3019-27.
25. Cochrane D, Bernales S, Jacobsen B, Cittelly D, Howe E, D’Amato N, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.
26. Rangel N, Rondon-Lagos M, Annaratone L, Osella-Abate S, Metovic J, Mano M, et al. The role of the AR/ER ratio in ER-positive breast cancer patients. Endocr Relat Cancer. 2018;25(3):163-72.
27. Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729-34.
28. van ‘t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
29. Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7.
30. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCG Abiolinks: a R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.
31. Team RC. R: a language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing; 2016. Disponible en:
32. Liao Y, Xia X, Liu N, Cai J, Guo Z, Li Y, et al. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene. 2018;37(14):1896-910.
33. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1-11.
34. Yu Q, Niu Y, Liu N, Zhang J, Liu T, Zhang R, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22(6):1288-94.
35. Grogg A, Trippel M, Pfaltz K, Ladrach C, Droeser R, Cihoric N, et al. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015;15:872.
36. Hanley K, Wang J, Bourne P, Yang Q, Gao A, Lyman G, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol. 2008;39(3):386-92.
37. Feng J, Li L, Zhang N, Liu J, Zhang L, Gao H, et al. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2017;36(20):2775-90.
38. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32(25):2794-803.
39. Al-Zahrani K, Cook D, Vanderhyden B, Sabourin L. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triplenegative breast cancer subtype by transcriptome profiling. Oncotarget. 2018;9(70):33348-59.
40. Daemen A, Manning G. HER2 is not a cancer subtype but rather a pancancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Res. 2018;20(1):8.
41. Chia K, Liu J, Francis G, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia. 2011;13(2):154-66.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.